GlassScriptPhysician profile
Robert Jordan Lakko
NPI 1174756340
$3,075.24
in general payments reported to CMS, 2019-2025
33 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $138 · 2021: $474 · 2022: $535 · 2023: $592 · 2024: $677 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $693.16 | 2021-2025 | |
| Glaxosmithkline, LLC. | $518.58 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $250.33 | 2021-2025 | Caplyta |
| Pfizer INC. | $140.29 | 2019-2025 | |
| Novo Nordisk INC | $137.48 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $136.72 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Mylan Specialty L.P. | $128.94 | 2020-2024 | Yupelri |
| Exact Sciences Corporation | $104.57 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.33 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $81.21 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $78.82 | 2023-2025 | Farxiga, Breztri |
| Sunovion Pharmaceuticals INC. | $69.58 | 2022 | |
| Amgen INC. | $64.38 | 2022-2023 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $59.89 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $51.65 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $41.67 | 2022 | |
| Grifols USA, LLC | $40.76 | 2020 | |
| Janssen Pharmaceuticals, INC | $36.36 | 2021-2022 | |
| Eisai INC. | $34.65 | 2021 | |
| Sanofi-Aventis U.S. LLC | $33.46 | 2022 | |
| Allergan, INC. | $31.98 | 2020 | |
| Urgo Medical North America, LLC | $26.93 | 2025 | Urgoclean Ag |
| Solventum Corporation | $26.13 | 2025 | V.A.C.Instill |
| Vanda Pharmaceuticals INC. | $24.15 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $22.97 | 2025 | Auvelity |
| Mimedx Group, INC. | $20.33 | 2025 | |
| Viatris Specialty LLC | $20.31 | 2025 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $18.16 | 2021 | |
| Antares Pharma, INC. | $17.69 | 2019 | |
| Horizon Therapeutics Plc | $16.46 | 2019 | |
| Abbott Laboratories | $16.08 | 2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $15.24 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lakko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.